Drilling Tests Main Showing Boundaries and First Holes at Steep Creek Zinc-Lead Target; Assays Pending

Drilling Tests Main Showing Boundaries and First Holes at Steep Creek Zinc-Lead Target; Assays Pending

Originally published via Source Article.

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) — Volaris Group today announced the acquisition of Matrix Booking Limited, a UK-based provider of meeting room and desk booking software used by government departments, NHS organizations and other public sector bodies across the United Kingdom.

Originally published via Source Article.

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (FSE: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, announces is pleased to announce its participation in the upcoming 3rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel. Anthony Durkacz, Co-founder and Executive Co-chairman of the board of Quantum BioPharma, will be presenting on the company’s recent milestones and future growth strategy.

Originally published via Source Article.

Drilling Tests Main Showing Boundaries and First Holes at Steep Creek Zinc-Lead Target; Assays Pending

Drilling Tests Main Showing Boundaries and First Holes at Steep Creek Zinc-Lead Target; Assays Pending

Originally published via Source Article.

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) — Volaris Group today announced the acquisition of Matrix Booking Limited, a UK-based provider of meeting room and desk booking software used by government departments, NHS organizations and other public sector bodies across the United Kingdom.

Originally published via Source Article.

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (FSE: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, announces is pleased to announce its participation in the upcoming 3rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel. Anthony Durkacz, Co-founder and Executive Co-chairman of the board of Quantum BioPharma, will be presenting on the company’s recent milestones and future growth strategy.

Originally published via Source Article.

Drilling Tests Main Showing Boundaries and First Holes at Steep Creek Zinc-Lead Target; Assays Pending

Drilling Tests Main Showing Boundaries and First Holes at Steep Creek Zinc-Lead Target; Assays Pending

Originally published via Source Article.

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) — Volaris Group today announced the acquisition of Matrix Booking Limited, a UK-based provider of meeting room and desk booking software used by government departments, NHS organizations and other public sector bodies across the United Kingdom.

Originally published via Source Article.

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (FSE: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, announces is pleased to announce its participation in the upcoming 3rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel. Anthony Durkacz, Co-founder and Executive Co-chairman of the board of Quantum BioPharma, will be presenting on the company’s recent milestones and future growth strategy.

Originally published via Source Article.

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (FSE: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, announces is pleased to announce its participation in the upcoming 3rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel. Anthony Durkacz, Co-founder and Executive Co-chairman of the board of Quantum BioPharma, will be presenting on the company’s recent milestones and future growth strategy.

Originally published via Source Article.